CAR-T trial for CLL (chronic lymphocytic leukemia) at City of Hope

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

City of Hope is one of the leading centers for novel cellular therapies. Slots for a Juno CAR-T CLL trial are now available. If you are a patient who has relapsed or refractory CLL (failed 2 or 3 lines of therapy) or who has progressed on ibrutinib AND is intolerant to ibrutinib, this is an opportunity to consider and to be considered for a CAR-T trial.

Please contact Lilly Li (jlillyli@coh.org or 626 359 8111 x80715) soon to find out more details, whether you qualify and if it makes sense as your next treatment.

Here is a link to the trial officially named

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory CLL or SLL (TRANSCEND-CLL-004)

https://clinicaltrials.gov/ct2/show/NCT03331198

February 21, 2018